We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Hemoglobin Cutoff Levels Evaluated for Anemia Among Healthy Individuals

By LabMedica International staff writers
Posted on 19 Aug 2021
Anemia, or low hemoglobin (Hb) concentration insufficient to meet an individual’s physiological needs, is the most common blood condition and affects approximately one-third of the world’s population.

Hb cutoffs to define anemia were first established in 1968 by experts who stated that, “over 95% of normal individuals are believed to show Hb levels higher than the cutoffs given” (i.e., 11.0 g/dL for children and 12.0 g/dL for non-pregnant women. More...
These cutoffs were derived from statistical cutoffs not linked with physiological or health outcomes.

A multidisciplinary team of medical scientists led by the Centers for Disease Control and Prevention (Atlanta, GA, USA) collected and evaluated from 30 household, population-based nutrition surveys of preschool children aged six to 59 months and non-pregnant women aged 15 to 49 years during 2005 to 2016 across 25 countries. Data analysis was performed from March 2020 to April 2021.

The team evaluated the current World Health Organization (WHO, Geneva, Switzerland) Hb cutoffs for defining anemia among persons who are apparently healthy and to assess threshold validity with a biomarker of tissue iron deficiency and physiological indicator of erythropoiesis (soluble transferrin receptor [sTfR]) using multinational data. All surveys were required to have Hb, ferritin, and inflammation, to assess the appropriateness of pooling Hb fifth percentile, but other indicators (vitamin A and malaria) were included only when available. The final healthy sample was 13,445 children (39.9% of the original sample of 33 699 children; 6,750 boys [50.2%]; mean [SD] age 32.9 ±16.0 months) and 25,880 women (56.0% of the original sample of 46,251 women; mean [SD] age, 31.0 ± 9.5] years).

The investigators reported that survey-specific Hb fifth percentile among children ranged from 7.90 g/dL in Pakistan, to 11.23 g/dL the USA, and among women from 8.83 g/dL in Gujarat, India to 12.09 g/dL in the USA. Intersurvey variance around the Hb fifth percentile was low 3.5% for women and 3.6% for children. Pooled fifth percentile estimates were 9.65 g/dL for children and 10.81 g/dL for women. The Hb-for-sTfR curve demonstrated curvilinear associations with sTfR inflection points occurring at Hb of 9.61 g/dL among children and 11.01 g/dL among women. The newly calculated multinational fifth percentile estimates of hemoglobin are more than 1.0 g/dL lower than current WHO cutoffs for defining anemia in apparently healthy people. Study results persisted when using higher ferritin cutoffs to define iron deficiency.

The authors concluded that on the basis of data from more than 39,000 individuals from 25 countries examined, the current WHO hemoglobin cutoff levels for defining anemia among preschool children and non-pregnant women were found to be significantly higher than the fifth percentile of Hb in apparently healthy individuals from most countries evaluated. The study was published on August 6, 2021 in the journal JAMA Network Open.

Related Links:
Centers for Disease Control and Prevention
World Health Organization



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Immunofluorescence Analyzer
IFA System
All-in-One Molecular System
AIO M160
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Technology

view channel
Image: Graphical Abstract (Wenjie Zhang, Zeyu Luo, Kaijie Liu, et al. Science Bulletin, 2026. doi:10.1016/j.scib.2026.09.016)

Multimodal AI Framework Aims to Guide Cancer Immunotherapy Decisions

Cancer immunotherapy has reshaped oncology, but heterogeneous responses and immune-related toxicities continue to complicate routine decision-making. Standard biomarkers, including programmed death-ligand... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.